Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Interleukin-2 and Interleukin-12 in Treating Patients With Refractory or Advanced Solid Tumors
This study is currently recruiting participants.
Study NCT00020163 Information provided by National Cancer Institute (NCI)
First Received: July 11, 2001 Last Updated: September 18, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Kidney Cancer
Lung Cancer
Ovarian Cancer
Sarcoma
Additional conditions recognized in this trial
Breast Neoplasms
Carcinoma, Renal Cell
Kidney Neoplasms
Lung Neoplasms
Neoplasms
Neuroectodermal Tumors, Primitive, Peripheral
Ovarian Neoplasms
More general conditions related to this trial
Adenocarcinoma
Adnexal Diseases
Breast Diseases
Carcinoma
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Kidney Diseases
Lung Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Connective and Soft Tissue
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Ovarian Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
aldesleukin
recombinant interleukin-12
Additional drug interventions recognized in this trial
Interleukin-12
More general drug interventions related to this trial
Adjuvants, Immunologic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
